Immune to Cancer: The CRI Blog
-
NY-ESO-1 Identified as a Promising Vaccine Target in Ovarian Cancer Patients
New study reveals effectiveness of immunotherapy vaccine against aggressive ovarian tumors.
-
Atezolizumab approved as first-line therapy for chemotherapy-ineligible bladder cancer patients
Atezolizumab’s third approval in the last year provides an important treatment option for a neglected population of…
-
TIME Magazine Names CRI’s Dr. James Allison One of 100 Most Influential People
TIME magazine honors Dr. Allison’s development of the first checkpoint immunotherapy, which has led to a revolution…
-
Meet Kathy: 100-Mile Rider in 2017 Answer to Cancer
On June 10, 2017, Kathy will ride for her husband, T.J.
-
PIMCO: Supporting a Future Immune to Cancer
PIMCO sponsors the 5K Family Fun Run/Walk of the 2nd annual Answer to Cancer and fields an…
-
AACR17 Update: Checkpoint Immunotherapy Clinical Trials in Melanoma and Lung Cancer
In-depth analysis of long-term clinical trial data provides important insights for doctors treating…
-
AACR17 Update: Checkpoints, Vaccines, and the Power of Prediction
Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches…
-
AACR17 Update: CAR T Cells, Regulatory T Cells, and the Future of Immunotherapy
Day two addressed several strategies to improve immunotherapy’s precision and effectiveness
-
AACR17 Update: Taking Immunotherapy to the Next Level
After cancer immunotherapy’s initial successes, new challenges are being confronted
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.